Inhibrx Biosciences, Inc. (INBX)
NASDAQ:INBX
Top Page
Inhibrx Biosciences Inc
(NASDAQ:INBX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$74.00
▼(-13.27% Downside)
Action:ReiteratedDate:04/10/26
The score is primarily held down by weak financial performance driven by persistent heavy cash burn, recurring losses, and limited revenue scale (despite improved leverage). Technicals are mixed with neutral momentum, while valuation is challenged by negative earnings and no dividend. A positive pipeline/catalyst update provides some support but remains outcome-dependent.
Positive Factors
Late-stage pipeline catalysts
The company has multiple milestone-driven programs (INBRX-106 readout, BLA plans and additional indication data) that create concrete, near-term value inflection points. Durable impact: positive clinical outcomes can unlock partnerships, regulatory paths and financing options that materially change capital structure and strategic flexibility.
Negative Factors
Persistent heavy cash burn
Consistently negative operating and free cash flow indicate the company cannot self-fund development. Durably, ongoing cash burn forces reliance on external financing, increasing dilution or refinancing risk, and constrains strategic choices if clinical milestones slip or fail to unlock new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage pipeline catalysts
The company has multiple milestone-driven programs (INBRX-106 readout, BLA plans and additional indication data) that create concrete, near-term value inflection points. Durable impact: positive clinical outcomes can unlock partnerships, regulatory paths and financing options that materially change capital structure and strategic flexibility.
Read all positive factors
Inhibrx Biosciences Inc (INBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.10B
Dividend YieldN/A
Average Volume (3M)220.34K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.11
Shares Outstanding14,607,036
10 Day Avg. Volume225,405
30 Day Avg. Volume220,340
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue857.12
Enterprise Value/Gross Profit-941.89
Enterprise Value/Ebitda-8.80
Forecast
1Y Price Target
$150.00Price Target Upside75.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.46
Revenue Forecast (FY)N/A
Inhibrx Biosciences Inc Business Overview & Revenue Model
Company Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candid...
How the Company Makes Money
null...
Inhibrx Biosciences Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.30M | 200.00K | 1.80M | 2.19M | 7.13M |
| Gross Profit | -1.18M | -2.08M | 609.00K | -107.99M | 4.44M |
| EBITDA | -132.54M | 1.70B | -206.69M | -125.82M | -75.37M |
| Net Income | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M |
Balance Sheet | |||||
| Total Assets | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M |
| Cash, Cash Equivalents and Short-Term Investments | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M |
| Total Debt | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M |
| Total Liabilities | 138.49M | 47.18M | 264.39M | 232.82M | 98.07M |
| Stockholders Equity | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M |
Cash Flow | |||||
| Free Cash Flow | -129.82M | -197.01M | -197.90M | -115.99M | -81.19M |
| Operating Cash Flow | -129.79M | -194.41M | -193.31M | -115.30M | -80.32M |
| Investing Cash Flow | -28.00K | -2.60M | -4.59M | -686.00K | -809.00K |
| Financing Cash Flow | 101.45M | 71.68M | 201.96M | 258.55M | 83.77M |
Inhibrx Biosciences Inc Technical Analysis
Positive
85.32
Price Trends
73.23
Positive
76.36
Positive
55.28
Positive
Market Momentum
0.20
Negative
61.14
Neutral
89.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Positive. The current price of 85.32 is above the 20-day moving average (MA) of 66.56, above the 50-day MA of 73.23, and above the 200-day MA of 55.28, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 61.14 is Neutral, neither overbought nor oversold. The STOCH value of 89.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBX.
Inhibrx Biosciences Inc Risk Analysis
Inhibrx Biosciences Inc disclosed 88 risk factors in its most recent earnings report. Inhibrx Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibrx Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.40B | -33.72 | -15.12% | ― | 1112.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $565.25M | -2.11 | -73.00% | ― | -91.16% | -112.24% | |
47 Neutral | $353.78M | -7.84 | -51.44% | ― | ― | 68.53% | |
46 Neutral | $1.10B | ― | -269.56% | ― | ― | ― | |
46 Neutral | $949.02M | -33.83 | -19.77% | ― | -10.26% | 144.62% | |
44 Neutral | $143.29M | -1.53 | -424.76% | ― | ― | 82.23% |
* Healthcare Sector Average
INBX
Inhibrx Biosciences Inc
77.46
65.67
557.00%
PRTA
Prothena
10.31
0.72
7.51%
CTMX
CytomX Therapeutics
4.39
3.76
595.72%
HUMA
Humacyte
0.67
-0.87
-56.49%
GLUE
Monte Rosa Therapeutics
17.55
13.12
296.16%
CADL
Candel Therapeutics
4.87
-0.08
-1.62%
Inhibrx Biosciences Inc Corporate Events
Business Operations and StrategyFinancial Disclosures
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy
Positive
Feb 23, 2026
On February 23, 2026, Inhibrx Biosciences posted an updated corporate investor presentation outlining its current programs, financial position, and upcoming catalysts, which it plans to use in meetings with the investment community. The materials ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.